ArticleProceedings of the National Academy of Sciences of the United States of America2026
Polycomb Repressive Complex 2 drives flow-sensitive endothelial states underlying vascular inflammation and disease.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polycomb Repressive Complex 2 drives flow-sensitive endothelial states underlying vascular inflammation and disease.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality worldwide, is driven by endothelial cell (EC) inflammatory activation and counterbalanced by protective mechanosensitive transcription factors Klf2 and Klf4 (Klf2/4). Plaques initiate in arterial curves or branches where disturbed shear stress (DSS) restrains Klf2/4 expression and promotes inflammatory activation of the endothelium. Importantly, DSS determines plaque vulnerability to rupture, the event that precipitates heart attack or stroke in advanced disease. However, the central determinants of endothelial inflammatory mechanotransduction and their interventional targeting to treat ASCVD pathology remain underexplored. Here, we identify Polycomb Repressive Complex (PRC) 2 as a potent, therapeutically targetable driver of vascular endothelial inflammation and ASCVD progression. PRC2 trimethylates Histone H3 Lysine27 in gene promoters/enhancers, including Klf2/4, to block gene transcription. Integrated mechanistic computation and experimental studies identified PRC2 as a central determinant of the EC state transition to inflammatory activation. PRC2 activity is elevated in endothelium from human ASCVD lesions. In murine models of acute and chronic vascular inflammation, interventional treatment with tazemetostat, a Federal Drug Administration (FDA)-approved inhibitor of the PRC2 methyltransferase EZH2, reduced endothelial inflammatory genes, slowed disease progression, and drastically improved markers of plaque stability. This study elucidates a fundamental epigenetic mechanism in vascular inflammation and suggests a potential treatment for advanced and chronic cardiovascular inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.